Study of REGN4461, a Leptin Receptor Agonist Antibody, in Patients With Generalized Lipodystrophy

NCT04159415 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

16

Enrollment

INDUSTRY

Sponsor class

Conditions

Generalized Lipodystrophy

Interventions

DRUG: Placebo
DRUG: Low-Dose REGN4461
DRUG: High-dose REGN4461

Sponsor

Regeneron Pharmaceuticals